AIMS: To obtain comprehensive pharmacokinetic and pharmacodynamic data for artesunate (ARTS) and its active metabolite dihydroartemisinin (DHA) following i.v. and oral administration of ARTS to patients with acute, uncomplicated falciparum malaria. METHODS:Twenty-six Vietnamese patients with falciparum malaria were randomized to receive either i.v. ARTS (120 mg; group 1) or oral ARTS (100 mg; group 2), with the alternative preparation given 8 h later in an open crossover design. Mefloquine (750 mg) was administered at 24 h. Plasma concentrations of ARTS and DHA were determined by h.p.l.c. assay. Pharmacokinetic parameters were calculated by non-compartmental methods. The time to 50% parasite clearance (PCT50) was calculated by linear interpolation of parasite density determinations. Linear least squares and multiple linear regression analyses were used to evaluate pharmacokinetic-pharmacodynamic relationships. RESULTS: Following i.v. bolus, ARTS had a peak concentration of 29.5 microM (11 mg l[-1]), elimination t1/2 = 2.7 min, CL = 2.33 l h(-1) kg(-1) and V = 0.14 l kg(-1). The Cmax for DHA was 9.3 microM (2.64 mg l[-1]), t1/2 = 40 min, CL =0.75 l h(-1) kg(-1) and V = 0.76 l kg(-1). Following oral ARTS, relative bioavailability of DHA was 82%, Cmax was 2.6 microM (0.74 mg l[-1]), t1/2 = 39 min, and MAT = 67 min. Overall, the PCT50 and fever clearance time (FCT) were 6.5 h and 24 h, respectively. There was no correlation between PCT50 or FCT and AUC, Cmax or MRT for DHA. CONCLUSIONS: Despite rapid clearance of ARTS and DHA in patients with uncomplicated falciparum malaria, prompt parasite and fever clearance were achieved. High relative bioavailability of DHA following oral ARTS administration, and clinical outcomes comparable with those after i.v. ARTS, support the use of the oral formulation in the primary care setting.
RCT Entities:
AIMS: To obtain comprehensive pharmacokinetic and pharmacodynamic data for artesunate (ARTS) and its active metabolite dihydroartemisinin (DHA) following i.v. and oral administration of ARTS to patients with acute, uncomplicated falciparum malaria. METHODS: Twenty-six Vietnamese patients with falciparum malaria were randomized to receive either i.v. ARTS (120 mg; group 1) or oral ARTS (100 mg; group 2), with the alternative preparation given 8 h later in an open crossover design. Mefloquine (750 mg) was administered at 24 h. Plasma concentrations of ARTS and DHA were determined by h.p.l.c. assay. Pharmacokinetic parameters were calculated by non-compartmental methods. The time to 50% parasite clearance (PCT50) was calculated by linear interpolation of parasite density determinations. Linear least squares and multiple linear regression analyses were used to evaluate pharmacokinetic-pharmacodynamic relationships. RESULTS: Following i.v. bolus, ARTS had a peak concentration of 29.5 microM (11 mg l[-1]), elimination t1/2 = 2.7 min, CL = 2.33 l h(-1) kg(-1) and V = 0.14 l kg(-1). The Cmax for DHA was 9.3 microM (2.64 mg l[-1]), t1/2 = 40 min, CL =0.75 l h(-1) kg(-1) and V = 0.76 l kg(-1). Following oral ARTS, relative bioavailability of DHA was 82%, Cmax was 2.6 microM (0.74 mg l[-1]), t1/2 = 39 min, and MAT = 67 min. Overall, the PCT50 and fever clearance time (FCT) were 6.5 h and 24 h, respectively. There was no correlation between PCT50 or FCT and AUC, Cmax or MRT for DHA. CONCLUSIONS: Despite rapid clearance of ARTS and DHA in patients with uncomplicated falciparum malaria, prompt parasite and fever clearance were achieved. High relative bioavailability of DHA following oral ARTS administration, and clinical outcomes comparable with those after i.v. ARTS, support the use of the oral formulation in the primary care setting.
Authors: D B Bethell; P Teja-Isavadharm; X T Cao; T T Pham; T T Ta; T N Tran; T T Nguyen; T P Pham; D Kyle; N P Day; N J White Journal: Trans R Soc Trop Med Hyg Date: 1997 Mar-Apr Impact factor: 2.184
Authors: S Looareesuwan; C Viravan; S Vanijanonta; P Wilairatana; P Suntharasamai; P Charoenlarp; K Arnold; D Kyle; C Canfield; K Webster Journal: Lancet Date: 1992-04-04 Impact factor: 79.321
Authors: S Krishna; T Planche; T Agbenyega; C Woodrow; D Agranoff; G Bedu-Addo; A K Owusu-Ofori; J A Appiah; S Ramanathan; S M Mansor; V Navaratnam Journal: Antimicrob Agents Chemother Date: 2001-02 Impact factor: 5.191
Authors: Juliana M Sá; Sarah R Kaslow; Michael A Krause; Viviana A Melendez-Muniz; Rebecca E Salzman; Whitney A Kite; Min Zhang; Roberto R Moraes Barros; Jianbing Mu; Paul K Han; J Patrick Mershon; Christine E Figan; Ramoncito L Caleon; Rifat S Rahman; Tyler J Gibson; Chanaki Amaratunga; Erika P Nishiguchi; Kimberly F Breglio; Theresa M Engels; Soundarapandian Velmurugan; Stacy Ricklefs; Judith Straimer; Nina F Gnädig; Bingbing Deng; Anna Liu; Ababacar Diouf; Kazutoyo Miura; Gregory S Tullo; Richard T Eastman; Sumana Chakravarty; Eric R James; Kenneth Udenze; Suzanne Li; Daniel E Sturdevant; Robert W Gwadz; Stephen F Porcella; Carole A Long; David A Fidock; Marvin L Thomas; Michael P Fay; B Kim Lee Sim; Stephen L Hoffman; John H Adams; Rick M Fairhurst; Xin-Zhuan Su; Thomas E Wellems Journal: Proc Natl Acad Sci U S A Date: 2018-11-19 Impact factor: 11.205
Authors: Ann K Miller; Nibedita Bandyopadhyay; Daniel G Wootton; Stephan Duparc; Paula L Kirby; Peter A Winstanley; Stephen A Ward Journal: Eur J Clin Pharmacol Date: 2009-06-11 Impact factor: 2.953
Authors: Julie A Simpson; Kris M Jamsen; Ric N Price; Nicholas J White; Niklas Lindegardh; Joel Tarning; Stephen B Duffull Journal: Malar J Date: 2009-08-06 Impact factor: 2.979